The management of the various types of shock, each characterized by its own combination of circulatory disturbances,1 is still far from perfect. Recently, the employment of intra-arterial transfusion2 and vasopressor drugs3 for shock has begun to receive increasing attention. The present report is a clinical evaluation of arterenol, a vasopressor drug, in the treatment of shock from various causes.
RATIONALE OF VASOPRESSOR DRUG THERAPY IN SHOCK
Whole blood is the most effective substance to combat shock due to hemorrhage; however, blood (or plasma) is not always immediately available, and other methods of treatment must be employed in the interim. Furthermore, blood and blood products, on occasion, are not effective in reversing the profound hypotension of severe blood loss, and adjuvant therapy is then desirable. Under these circumstances, vasopressor drug therapy would be indicated to combat the severe peripheral vascular collapse.Severe cardiogenic shock, initiated by the inability
Miller AJ, Shifrin A, Kaplan BM, Gold H, Billings A, Katz LN. ARTERENOL IN TREATMENT OF SHOCK. JAMA. 1953;152(13):1198–1201. doi:10.1001/jama.1953.03690130014003
Customize your JAMA Network experience by selecting one or more topics from the list below.